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Abstract Patients with some neurological lysosomal stor-
age disorders (LSD) exhibit improved clinical signs
following bone marrow transplantation (BMT). The failure
of mucopolysaccharidosis (MPS) type IIIA patients and
adult mice with the condition to respond to this treatment
may relate to factors such as impaired migration of donor-
derived cells into the brain, insufficient enzyme production
and/or secretion by the donor-derived microglial cells, or
the age at which treatment is initiated. To explore these
possibilities, we treated neonatal MPS IIIA mice with
whole unfractionated bone marrow and observed that
nucleated blood cell reconstitution occurred to a similar
degree in MPS IIIA mice receiving green fluorescent
protein (GFP)-expressing normal (treatment group) or
MPS IIIA-GFP marrow (control group) and normal mice
receiving normal-GFP marrow (control group). Further,
similar distribution patterns of GFP+ normal or MPS IIIA
donor–derived cells were observed throughout the MPS
IIIA mouse brain. We demonstrate that N-sulfoglucosamine
sulfohydrolase (SGSH), the enzyme deficient in MPS IIIA,
is produced and secreted in a manner proportional to that of
other lysosomal enzymes. However, despite this, overall
brain SGSH activity was unchanged in MPS IIIA mice
treated with normal marrow and the lysosomal storage
burden in whole brain homogenates did not decrease, most
likely due to donor-derived cells comprising <0.24% of
total recipient brain cells in all groups. This suggests that
the failure of MPS IIIA patients and mice to respond to
BMT may occur as a result of insufficient donor-derived
enzyme production and/or uptake by host brain cells.
Introduction
Lysosomal storage disorders (LSD) are a group of inherited
conditions that most commonly result from the absence of a
catabolic enzyme, causing the accumulation of partially
degraded substrates. In Sanfilippo syndrome, or mucopoly-
saccharidosis (MPS) types IIIA, B, C or D, degradation of
the glycosaminoglycan heparan sulfate is incomplete and as
a result heparan sulfate–derived oligosaccharide fragments
accumulate within the lysosome. Patients afflicted with
Sanfilippo syndrome are generally diagnosed between
2–6 years of age and show a gradual deterioration of central
nervous system function, increased aggression, hyperactivity,
and sleep disturbance (Neufeld and Muenzer 2001). Several
naturally occurring animal models of MPS IIIA have been
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identified, including a mouse model resulting from a
missense mutation that causes an amino acid change from
an aspartic acid to an asparagine at position 31 of the
lysosomal enzyme N-sulfoglucosamine sulfohydrolase
(SGSH; EC 3.10.1.1) (Bhaumik et al. 1999; Bhattacharyya
et al. 2001). Congenic C57BL/6 MPS IIIA mice display
reduced SGSH activity resulting in accumulation of heparan
sulfate–derived disaccharides, GM2 and GM3 gangliosides
and unesterified cholesterol, as well as behavioral changes
such as reduced learning ability in the Morris Water Maze
test, changes in open field activity, and altered anxiety-
related behaviors (Crawley et al. 2006; Fraldi et al. 2007;
Lau et al. 2008, 2010).
Allogeneic hematopoietic stem/precursor cell transplan-
tation (BMT) halts disease progression in several neuro-
logical LSD, such as MPS type I and metachromatic
leukodystrophy, provided that a suitable donor match can
be identified and that the transplant is undertaken early in
the disease course (Shapiro et al. 1995). Despite the
successful engraftment of donor cells, it appears that
BMT in MPS IIIA patients is unable to improve or stabilize
cognitive function (Klein et al. 1995; Sivakumur and
Wraith 1999). Umbilical cord blood stem cell transplants
have also been undertaken in Sanfilippo patients, with a
5-year probability of survival of 56% (Prasad et al. 2008).
Two of the children treated at less than 2 years of age who
survived the transplant may have had a modest improve-
ment in cognitive skills, though were still developmentally
delayed overall (Prasad et al. 2008). Pre-symptomatic MPS
IIIA mice transplanted at 4 weeks of age show complete
engraftment of donor cells in peripheral blood as well as
high levels of SGSH activity and reduced heparan
sulfate–derived oligosaccharide storage in the bone marrow
compartment, measured using the disaccharide marker
GlcNS-UA (Lau et al. 2010). While there was a reduction
in brain GlcNS-UA of 27%, this was insufficient to mediate
a clinical improvement in the behavioral phenotype of the
transplanted mice.
The basis of the differential response of patients with
MPS IIIA and MPS I or metachromatic leukodystrophy to
BMT is not known. One possibility is that the high
concentration of undegraded heparan sulfate–derived frag-
ments in host MPS IIIA tissues reduces the mobilization of
donor bone marrow–derived cells into circulation, thereby
resulting in fewer engrafted donor cells within the affected
brain. Heparan sulfate proteoglycans modulate a wide
variety of biological interactions, including the binding of
several key molecules involved with hematopoietic stem
cell homing and mobilization. For example, heparin, a
highly sulfated form of heparan sulfate, forms tight
complexes with neutrophil elastase and cathepsin G which
render these proteases 2–5 times less active than their free
counterparts toward natural and synthetic substrates
(Frommherz et al. 1991). Considering that neutrophil
elastase and cathepsin G proteolysis mobilizes hemato-
poietic precursor/progenitor cells into circulation (Levesque
et al. 2001), reduced activity of these enzymes due to
interactions with heparan sulfate could potentially result in
inefficient repopulation of donor-derived cells in blood and
organs following BMT. Heparan sulfate–derived GlcNS-
UA is elevated 15-fold in newborn MPS IIIA mouse brain,
progressively increasing to maximal levels exceeding 250-
fold by 13 weeks of age (Crawley et al. 2006). Therefore,
transplanting mice in the neonatal period, when GlcNS-UA
is less abundant, may improve donor-derived cell mobiliza-
tion and the efficacy of BMT. In the murine MPS VII
model, BMT is more effective when delivered to neonatal
compared to adult mice (Birkenmeier et al. 1991; Sands
et al. 1993). Also, the clinical efficacy of cell-mediated
therapies, such as BMT, is impacted by the ability of both
the transplanted cells to produce and secrete enzyme
containing mannose-6-phosphate moieties and the affected
host cells to efficiently internalize this enzyme and target it
toward the lysosome via the mannose-6-phosphate pathway
(reviewed in Kornfeld 1992). In this study, we have
examined several factors that may influence the outcome
of BMT in MPS IIIA mice and the effect of neonatal
transplantation on neuropathological storage.
Materials and Methods
Mice and Genotyping
All procedures were approved by the institutional Animal
Ethics Committee and were conducted as per the guidelines
of the National Health and Medical Research Council of
Australia. MPS IIIA B6.Cg-Sgshmps3a (“MPS IIIA”) and
unaffected (wild-type or heterozygous; subsequently
referred to as “normal”) mice were obtained from a
breeding colony maintained at the Women’s and Children’s
Hospital (Crawley et al. 2006). The genotypes of the mice
were determined from a toe clip collected at 5–7 days of
age by extracting genomic DNA by overnight incubation at
37 C in 50 mL of 50 mM Tris, pH 8.0, 2 mM NaCl, 1 mM
EDTA, 0.5% (v/v) Tween20, and 0.5% (v/v) Triton X-100
supplemented with 1.2 mg/mL proteinase K. After heating
at 95 C for 10 min, 1–2 mL of clarified lysate was
amplified with forward primer 50-NNT CTG TCT TCC
TCA GCG-30, reverse primer 50-GAT AAG GCT GTG
GCG GGA CAG GG-30 (final concentration of 4 ng/mL of
each primer), 0.2 mM dNTP (Roche, Mannheim,
Germany), and 1.25 U HotStarTaq DNA Polymerase
(Qiagen, Doncaster, Australia) in a 50 mL reaction by
denaturing at 94C for 15 min followed by 35 cycles of
94C for 45 s, 55C for 45 s, and 72C for 40 s, and a
5 min final extension at 72C. After visualization of the
105 bp PCR product, amplified DNAwas digested with 5 U
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AciI (New England Biolabs, MA, USA) at 37 C before
electrophoresis through a 4.5% (w/v) agarose gel. As the
G91A mutation abolishes an AciI site, wild-type mice
display bands at 74, 16, and 15 bp while MPS IIIA mice
display bands at 90 and 15 bp. Heterozygote mice display
bands at 90, 74, 16, and 15 bp.
Breeding pairs of C57BL/6-Tg(UBC-GFP)30Scha/J
mice (Schaefer et al. 2001) were purchased from the
Jackson Laboratory (ME, USA) and a pedigreed breeding
colony was maintained at the Women’s and Children’s
Hospital. These mice express green fluorescent protein
(GFP) under the control of the human ubiquitin C promoter
and wild-type levels of SGSH and are subsequently referred
to as “normal-GFP” mice. Mice were confirmed as
GFP-positive by viewing a toe clip under ultraviolet light.
A normal-GFP dam (SGSH+/+GFP+/+) was mated with an
MPS IIIA stud (SGSH/GFP/) to generate offspring
heterozygous for the SGSH and GFP genes. The F1 animals
were inter-crossed and the resultant F2 offspring were
assessed for GFP expression (see “Flow Cytometry” section)
and normal, carrier, or affected SGSH gene status. A brother/
sister founder pair of MPS IIIA mice homozygous for the
GFP allele (“MPS IIIA-GFP”; SGSH/GFP+/+) were used
to establish a pedigreed colony.
Neutrophil Elastase and Cathepsin G Activity
Following CO2-mediated euthanasia, bone marrow extra-
cellular fluid was extracted from 6-week-old normal and
MPS IIIA mice by flushing the hind-leg bones with 0.5 mL
ice-cold phosphate-buffered saline (PBS) using a 21 G
needle (n ¼ 9–10 mice per group). For neutrophil elastase
activity, 10 mL of sample was diluted with 90 mL of 0.1 M
Tris–HCl, pH 7.5, 0.5 M sodium chloride, and 0.01% (v/v)
sodium azide and then mixed with an equal volume of
800 mM MeOSuc-Ala-Ala-Pro-Val-pNA substrate (Calbio-
chem, Australia). For cathepsin G activity, 10 mL of sample
was diluted in 90 mL of 0.1 M Tris–HCl, pH 8.3, 0.01%
(v/v) sodium azide and mixed with 100 mL of 800 mM
Suc-Ala-Ala-Pro-Phe-pNA (Calbiochem, Australia). Stan-
dard curves were prepared using recombinant neutrophil
elastase (Calbiochem, Australia; 0–128 mU/mL) or
cathepsin G (Calbiochem, Australia; 0–20 mU/mL).
Following a 3-h incubation at 37 C, the absorbance was
measured on a Victor3™ multilabel reader (Perkin Elmer)
at 405 nm to quantitate the amount of cleaved pNA.
Protease activity was normalized to total protein content as
determined by bicinchoninic acid assay (Pierce, IL).
Transplantation and Necropsy
Donor normal-GFP or MPS IIIA-GFP mice (8–10 weeks
old) were treated with 5-fluorouracil (150 mg/kg intraperito-
neal; Sigma, MO, USA). Three days later, the mice were
euthanized and donor bone marrow cells were harvested by
flushing the hind-leg bones with Dulbecco’s modified
Eagle’s medium (DMEM) containing 2% fetal calf serum
(FCS) and 50 U penicillin/0.05 mg/mL streptomycin (Sigma,
MO, USA) using a 23 G needle (Lau et al. 2010). The cells
were passed through a 100 mm cell strainer and red blood
cells were lysed with Gey solution (155 mM ammonium
chloride, 10 mM potassium hydrogen carbonate) at 37 C for
10 min. Viable cells were counted with trypan blue dye
(Sigma, MO, USA) and resuspended in PBS containing 30
U/mL heparin. Normal and MPS IIIA recipients (3 days old)
were placed into a polypropylene container subdivided into
2.5 cm  2.5 cm compartments and irradiated with 4 Gy
using a megavoltage linear accelerator at a dose rate of
2 Gy/min. The pups then received 1–2  106 donor cells
(in 30 mL total volume) intravenously via the superficial
temporal vein. In the pilot study, 3-day-old mice were
irradiated with 6 Gy prior to transplantation.
At 8 weeks post-transplant, the recipient mice were
overdosed with CO2 and whole blood collected via cardiac
puncture and transferred to an EDTA-coated vacuette. The
brain was removed, divided along the midline and one
hemisphere was further sectioned in the coronal plane into
five 2-mm thick slices and frozen at 20 C. The other
hemisphere was post-fixed in 4% paraformaldehyde in PBS
at 4 C for 24 h, cryo-protected in 30% (w/v) sucrose in PBS
(Sigma, MO, USA) and embedded in Tissue-Tek OCT
compound (Tokyo, Japan).
Flow Cytometry
The /, /+, or +/+ status of the GFP gene during the
generation of the MPS IIIA-GFP strain was determined in
up to 20 mL of blood collected from the saphenous vein
using 4% (w/v) EDTA-treated capillary tubes. The percent-
age of donor cell reconstitution in leukocytes was deter-
mined in duplicate samples of 50 mL whole blood taken at
euthanasia (Lau et al. 2010). Erythrocytes were lysed in
2 mL of FACS lysing solution (BD Biosciences, NJ, USA).
The leukocytes were blocked with IntraGam®P (CSL Ltd,
Parkville, Australia), labeled with PE-Cy5-conjugated
anti-CD45 (1:10 dilution; BD Biosciences, NJ, USA) and
then washed with 0.5% (w/v) bovine serum albumin
(Sigma, MO, USA) in IsoFlow Sheath Flow (Beckman
Coulter, CA, USA). The cells were then analyzed on a
FACSCalibur flow cytometer (Beckton Dickson, NJ, USA)
equipped with CellQuest software (version 3.1).
SGSH Activity and GlcNS-UA Measurement in Tissue
Homogenates
Livers, spleens, and brain tissues (slice 2) were homogenized
in 500 mL of 20 mM Tris, 500 mM sodium chloride, pH 7.4,
and sonicated twice for 30 s each. Samples for SGSH activity
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measurement were dialyzed overnight in 200 mM sodium
acetate, pH 5.2, and incubated with 400 pmol of a tritiated,
heparin-derived tetrasaccharide substrate (Hopwood and
Elliott 1982) at 60 C. The amount of substrate and product
were separated and quantified by high-performance liquid
chromatography and normalized to total protein content
(MicroBCA kit; Pierce, IL, USA).
The relative amount of a disaccharide marker (GlcNS-
UA) of heparan sulfate storage was determined in brain
samples from experimental mice or from untreated MPS
IIIA brain as an internal control (50 mg total homogenate
per sample). The tissues were derivatized with 1-phenyl-3-
methyl-5-pyrazolone (Sigma, MO, USA) and assessed by
liquid chromatography electrospray ionization tandem mass
spectrometry analysis using a PE Sciex API 4000 QTRAP
triple quadrupole mass spectrometer with a turbo spray
source, as previously described (Hemsley et al. 2009). The
intra-assay coefficient of variation of the quality control
brain homogenate was 4.9%.
Quantitative Real-Time PCR
Genomic DNA was extracted from brain slices 3 and 5
according to published methods (Joshi et al. 2008), except
that DNA was precipitated with 0.1x volume of 3 M
sodium acetate and 2 volumes of 100% ethanol. The
purity and concentration of DNAwas determined at 260 nm
using a Nanodrop (ND-1000, version 3.7.0; Thermo
Scientific, Scoresby, Australia).
Primer Express Software (version 3; Applied Biosys-
tems, CA, USA) was used to design EGFP forward
(5´-GACGACGGCAACTACAAGAC-3´) and reverse
(5´-GTCCTCCTTGAAGTCGATGC-3´) primers and
hypoxanthine guanine phosphoribosyl transferase (HPRT)
forward (5´-GTGGGAATGCGCAATCACT-3´) and reverse
(5’-TCCACTCTTCAGGTGGAAAATAGG-3´) primers.
The efficiency (E) of each primer set was determined using
10-fold dilutions of normal-GFP genomic DNA (0.05 to
500 ng) and was calculated from the slope of the standard
curve (cycle threshold (Ct) against log genomic DNA
concentration) using the formula E ¼ 1 +10(1/slope).
Real-time quantitative PCR reactions were carried out
with an Applied Biosystems 7300 Real-Time PCR System
in 96-well clear optical reaction plates with optical adhesive
covers (Applied Biosystems, CA, USA). Reactions (30 mL)
were performed in triplicate, with 100 ng genomic DNA,
SYBR® Green PCR master mix (Applied Biosystems, CA,
USA) and either EGFP (3 mM) or HPRT primers (10 mM).
The cycling conditions employed were 50 C for 2 min,
95 C for 10 min, followed by 40 cycles of 95 C for 15 s
and 60 C for 1 min. Ct values were determined using the
7000 Sequence Detection software (v1.3; Applied
Biosystems, CA, USA). The relative number of EGFP
copies versus HPRT copies was determined using the
method of Pfaffl (2001) and expressed as a percentage of
GFP-expressing cells compared to a reference untreated
normal-GFP mouse brain (100% GFP-positive).
GM3 Ganglioside Immunohistochemistry and GFP
Visualization
Tissues were processed, imaged, and assessed in a single
batch by an experimenter without knowledge of the
genotype/treatment status of the samples. Frozen brain
sections (6 mm thick) were cut in the sagittal plane and
collected onto Superfrost Plus slides (Menzel-Glaser,
Braunschweig, Germany). GM3 ganglioside secondary
storage was quantitated by staining with a monoclonal
anti-GM3 antibody (Seikagaku Biobusiness Corporation,
Tokyo, Japan; 1:750) using published methods (Lau et al.
2010). For GFP imaging, cryo-sections were rinsed in PBS
and mounted with Vectashield mounting media containing
4',6-diamidino-2-phenylindole (DAPI) to label all nuclei
(Vector Laboratories, CA, USA). Images were captured
using an Olympus Colorview Soft Imaging System and an
Olympus BX41 (GM3 ganglioside) or BX61 (GFP)
microscope, and the percentage of immunostained area
was determined with AnalySIS Lifescience software
(version 2.8, Build1235, Olympus Soft Imaging Solutions).
Cell Culture
All cells were derived from neonatal mice euthanized by
decapitation at 0–4 days of age. Skin fibroblast cultures
(Villegas and McPhaul 2005) were grown in DMEM/
Nutrient Mixture F-12 Ham (Sigma, MO, USA) with 20%
FCS (ThermoElectron Corporation, Melbourne, Australia),
2 mM glutamine (SAFC Biosciences, KS, USA) and 50 U
penicillin/0.05 mg/mL streptomycin (Sigma, MO, USA).
Mixed neural cells derived from whole brain (Sutherland
et al. 2008) were maintained in DMEM (Sigma, MO, USA)
with 5% FCS (ThermoElectron Corporation, Melbourne,
Australia), 5% horse serum (Institute of Medical and
Veterinary Science, Adelaide, Australia), 2 mM glutamine
(SAFC Biosciences, KS, USA), and 50 U penicillin/
0.05 mg/mL streptomycin (Sigma, MO, USA). Cells were
cultured at 37 C with 5% CO2.
Lysosomal Enzyme Activity Assays
Neural cells and fibroblasts were cultured until confluence.
The cells were then given a media change and cultured for
1 week without further media changes. Conditioned media
was collected and stored frozen and control unconditioned
media samples were also included. The cells were detached
with 10% trypsin (SAFC Biosciences, KS, USA) in PBS
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(Sigma, MO, USA), centrifuged at 6,240g for 5 min and
resuspended in 300 mL of 20 mM Tris, 500 mM sodium
chloride, and pH 7.4. Samples were subjected to six cycles
of freezing/thawing in a slurry of dry ice and ethanol.
SGSH activity was determined by mixing 8 mL of sample
with 3 mL of 200 mM sodium acetate, pH 5.2, and 1 mL of
tritiated, heparin-derived tetrasaccharide substrate (400
pmol) and incubating for 16 h at 60 C. The conversion of
substrate into product was then measured as described for
brain homogenates. For all other enzyme assays, 10 mL of
sample was mixed with 40 mL of 0.9%NaCl and 50 mL of the
appropriate substrate and incubated at 37 C. After 1
h (a-mannosidase and a-fucosidase), 2 h (a-iduronidase;
IDUA), or 4 h (a-N-acetylglucosaminidase; NAGLU), the
reaction was quenched with 1.5 mL glycine buffer
(200 mM glycine, 125 mM sodium carbonate, pH 10.7)
and the amount of free 4-methylumbelliferone (4MU) was
measured on a Perkin Elmer LS-50B spectrofluorometer.
The substrates used were 4MU-2-acetomido-2-deoxy-a-D-
glucopyranoside (NAGLU; 2 mM in 200 mM sodium
acetate, pH 4.3; Toronto Research Chemicals, North York,
Canada), 4MU-a-L-idopyranosiduronic acid (IDUA; 2 mM
in formate buffer, pH 3.6; Toronto Research Chemicals,
North York, Canada), 4MU-a-mannopyranoside (a-manno-
sidase; 4 mM in acetate buffer, pH 4.0; Melford
Laboratories, Chelsworth, UK), and 4MU-a-L-fucopyrano-
side (a-fucosidase; 1 M in citrate phosphate buffer, pH 5.0;
Melford Laboratories, Chelsworth, UK).
The activity in unconditioned media controls was
subtracted from activity measured in the conditioned media
samples to determine the secreted activity in the media. The
calculated activity in each sample was then corrected for total
protein content to give a total amount of intracellular or
extracellular activity. Secreted enzyme activity was calculated
as the percentage of extracellular activity as a proportion of the
sum of intracellular and extracellular activity.
GlcNS-UA Determination in Co-cultured Normal and MPS
IIIA Cells
Normal-GFP and MPS-GFP fibroblasts (2 weeks post-
confluent) were plated into 6-well trays at various ratios of
normal and MPS IIIA cells, with each well containing
5  106 cells in total, based on a previous report that the
number of microglia in the brain is thought to remain
constant in adulthood (Lawson et al. 1992) and therefore in
a transplantation setting the donor microglia would replace
recipient microglia rather than supplement microglial
numbers. To prevent clonal dominance of normal-GFP
cells in the co-cultured populations, the cells were detached
after 48 h with 10% trypsin (SAFC Biosciences, KS, USA)
in PBS (Sigma, MO, USA), centrifuged at 6,240g for 5 min
and resuspended in 150 mL of 20 mM Tris, 500 mM
sodium chloride, pH 7.4. The cells were sonicated twice for
30 s and the total protein content was quantitated using a
MicroBCA kit (Pierce, IL, USA). The relative amount of
GlcNS-UA was determined in 100 mg of cell extract,
as described for brain homogenates. The intra-assay
coefficient of variation of an internal quality control sample
of cultured cells was 2.6%.
Statistics
Data are expressed as the mean  SEM. Data were
analyzed using one-way ANOVA with GraphPad Prism
software (v.502) with post hoc comparisons made using the
Bonferroni correction factor or with unpaired t-tests.
Statistical significance was considered to be P < 0.05.
Results
Donor Leukocyte Engraftment Following Myeloreduction
Three-day-old normal and MPS IIIA pups were trans-
planted with syngeneic GFP-expressing mononuclear bone
marrow cells following irradiation with 4 Gy. The three
treatment groups were (1) normal recipients receiving
normal-GFP donor cells (n ¼ 9 mice; 8 male, 1 female),
(2) MPS IIIA recipients receiving MPS IIIA donor cells
(n ¼ 5 mice; 4 male, 1 female), and (3) MPS IIIA
recipients receiving normal-GFP donor cells (n ¼ 7 mice;
3 male, 4 female). The body weights of the three cohorts
were indistinguishable at 2 months post-transplantation
(P > 0.05; Fig. 1a). Quantitation of donor-derived periph-
eral blood leukocyte reconstitution revealed no significant
differences in mobilization between the transplanted groups
of mice, with an average of 25%, 24% and 21%
CD45+GFP+ donor cells measured at 8 weeks post-
transplantation in control normal mice, control MPS IIIA
mice, and treated MPS IIIA mice, respectively (Fig. 1b).
Further, the catalytic activity of two serine proteases
involved in the mobilization of hematopoietic precursor/
progenitor cells was determined in bone marrow extracel-
lular fluid from 6-week-old mice. Although there was a
trend toward an increase in neutrophil elastase activity in
MPS IIIA mice, statistically significant differences were not
measured (P > 0.05; Fig. 1c). Likewise, no significant
differences in cathepsin G activity were measured between
genotype groups (P > 0.05; Fig. 1c).
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Fig. 1 Effect of transplantation of neonatal MPS IIIA mice
preconditioned with 4 Gy. (a) The weight of MPS IIIA recipient mice
transplanted with normal-GFP donor bone marrow (“MPS IIIA
Treated”; n ¼ 7 mice) and transplanted control groups of normal
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GFP-Expressing Donor Cells Repopulate Throughout the
Brain, but at Low Levels
To verify that donor-derived cells had successfully migrated
and engrafted within the central nervous system, GFP-
expressing cells were visualized in brain tissue sections.
GFP-positive cells were widely distributed throughout the
brains of all groups of transplanted mice, including regions
such as the cerebellum, cerebral cortex, hippocampus,
thalamus, inferior colliculus, superior colliculus, and
brainstem (Fig. 1d and Supplementary Figure 1). To obtain
a quantitative measure of the number of donor-derived cells
in the brain, the relative GFP transgene copy number
(compared to the HPRT gene as an endogenous control)
was determined in hemi-coronal brain slices by quantitative
real-time PCR and compared to untreated transgenic mouse
brains that expressed GFP in all nucleated cells (i.e., all
cells except for red blood cells). Initial validation experi-
ments showed that the amplification efficiency was similar
for the GFP and HPRT primer sets (101.6% and 95.4%,
respectively). In addition, dissociation curve analysis
demonstrated the formation of a single peak for each
primer set, with a melting temperature of 84 C and 80 C
for GFP and HPRT primers, respectively.
The relative number of GFP transgene copies was
examined in brain slices 3 and 5 of transplanted mice by
real-time quantitative PCR. In brain slice 3, the relative
level of GFP repopulation was, on average, 0.1–0.2%, with
no difference detected between treatment/genotype groups
(Fig. 1e). The maximum percentage of GFP engraftment
measured in the brain was 0.52% in a normal transplanted
control mouse. A similar low level of donor cell repopula-
tion was measured in brain slice 5 (0.1–0.2% on average;
Fig. 1f).
Effect of Transplantation on SGSH Activity and Substrate
Accumulation
To determine the effect of donor cell transplantation,
SGSH activity was measured in liver, spleen, and brain
homogenates. In the liver, MPS IIIA mice transplanted with
MPS IIIA bone marrow displayed 1.8% of the SGSH
activity measured in normal mice transplanted with normal
bone marrow (Fig. 1g). Transplantation of normal-GFP
bone marrow cells in MPS IIIA mice had no impact on liver
SGSH activity (1.3% of wild-type SGSH activity). Similar
trends were observed in the spleen (Fig. 1h) and brain
parenchyma (Fig. 1i), with transplantation of normal-GFP
cells into MPS IIIA recipients yielding no significant
differences in SGSH activity compared to control-trans-
planted MPS IIIA mice.
Heparan sulfate–derived GlcNS-UA was considerably
elevated in the brain of control transplanted MPS IIIA mice
receiving MPS IIIA-GFP bone marrow relative to normal
mice transplanted with normal-GFP donor cells (165-fold
normal; P < 0.0001; Fig. 1j). Transplantation of normal-
GFP bone marrow did not significantly reduce the relative
level of GlcNS-UA in MPS IIIA recipient mouse brain
(162-fold normal).
The effect of treatment on secondary storage products
was also examined at 8 weeks post-transplant. In both the
inferior colliculus (Fig. 1k) and caudal cortex (Fig. 1l),
numerous GM3 ganglioside-immunoreactive puncta were
observed in MPS IIIA mice transplanted with MPS
IIIA-GFP bone marrow. In contrast, GM3 ganglioside
immunoreactivity was infrequently observed in the trans-
planted normal control mice. Delivery of normal-GFP
donor bone marrow to MPS IIIA recipient mice had no
observable treatment effect on the amount of GM3
ganglioside immunoreactivity (Fig. 1l-k).
The Percentage of Extracellular SGSH Activity is Similar
to Other Lysosomal Enzymes
We next examined whether the proportion of secreted
SGSH and NAGLU (EC 3.2.1.50; deficient in MPS IIIB) in
wild-type cells was altered compared to the hydrolases
deficient in MPS I, a-mannosidosis, and a-fucosidosis (i.e.,
neurodegenerative LSD that are successfully treated by
allogeneic BMT). In skin fibroblast cultures, SGSH activity
Fig. 1 (continued) mice receiving normal-GFP cells (“Normal”;
n ¼ 9 mice) and MPS IIIA mice receiving MPS IIIA cells (‘MPS
IIIA’; n ¼ 5 mice) was recorded at 8 weeks post-treatment. (b) The
percentage of donor-derived GFP+CD45+ leukocytes was
measured by flow cytometry. (c) The catalytic activity of two
proteolytic enzymes that are involved with the mobilization of
bone marrow cells into circulation was measured using chromo-
genic substrates in bone marrow extracellular fluid harvested from
untreated normal (open bars) and MPS IIIA (filled bars) mice
(n ¼ 9-10 mice per group). (d) Cryo-sections were examined for the
presence of donor-derived GFP-expressing cells (green) compared
to the total number of DAPI-stained cell nuclei (blue) in the
cerebellum. Scale bar is 100 mm. The relative GFP transgene copy
number (compare to the HPRT gene as an endogenous control)
was determined via quantitative real-time PCR in transplanted
mouse (e) brain slice 3 and (f) slice 5. An untreated transgenic
normal-GFP mouse brain was used as a calibrating sample
(100%). (g) Liver, (h) spleen, and (i) brain SGSH activity was
measured in tissue homogenates using a radiolabeled tetrasacchar-
ide substrate and HPLC separation. (j) The relative amount of
GlcNS-UA disaccharide was determined by tandem mass spec-
trometry as a measure of the amount of primary storage material
in the transplanted mouse brain. The effect of treatment on GM3
ganglioside storage in the brain was quantitated in the (k) inferior
colliculus and (l) caudal cortex using immunohistological methods
and AnalySIS Lifescience software. All data are expressed as the
mean  SEM. *P < 0.05, ***P < 0.001 versus the control-trans-
planted MPS IIIA control group
◂
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was reduced in cell extracts compared to all other assayed
lysosomal enzymes (Fig. 2a). Similar trends were observed
in neural cells and in media samples of both cell types,
although not all differences reached statistical significance
(Fig. 2b–d). The proportion of extracellular SGSH activity
was comparable to the percentage of extracellular NAGLU
and a-iduronidase (EC 3.2.1.76) activity in both cell
populations and was significantly higher than that of
a-fucosidase (EC 3.2.1.51; Fig. 2e–f). a-Mannosidase
(EC 3.2.1.24) was the only lysosomal enzyme that was
measured at a significantly higher percentage of extracel-
lular activity compared to SGSH (Fig. 2e–f).
Preconditioning with Higher Irradiation Doses Improves
Donor Cell Engraftment but Induces Acute Radiation
Syndrome Symptoms
In an attempt to increase the degree of donor-derived cell
engraftment in affected organs, including the brain, 3-day-old
normal mouse pups were preconditioned with a higher
myeloablative dose of 6 Gy before normal-GFP donor cell
infusion (n ¼ 4 mice) and compared to a second cohort of
normal mice irradiated with 4 Gy and transplanted with
normal-GFP cells (n ¼ 5 mice). At 4 weeks post-transplant,
analysis of CD45+GFP+ peripheral blood leukocytes showed
that the donor-type chimerism was 10  3% in mice
preconditioned with 4 Gy. Donor cell engraftment was
significantly improved following preconditioning with
6 Gy, with 37  4% CD45+GFP+ donor cells measured
(P < 0.001). As observed in the earlier study, mice
irradiated with 4 Gy showed no signs of acute radiation
syndrome. In contrast, recipient pups that received 6 Gy
displayed significant growth retardation at 4 weeks post-
treatment (P < 0.05), weighing 28% less than mice irradi-
ated with 4 Gy, and also developed ataxia and involuntary
tremors. Due to the severity of the side effects of the
preconditioning regime in the latter group of mice, the study
was terminated and the mice euthanized at 4 weeks of age.
Reduction of Substrate in MPS IIIA Cultured Cells After
Co-incubation with Normal Cells
Previously, we achieved a 27% reduction in brain GlcNS-
UA when approximately 3% of the total brain cells were of
donor origin (unpublished data and Lau et al. 2010). Cells
of macrophage/microglial origin have been estimated to
make up to 12% of total brain cells (Lawson et al. 1990),
which raised the following question: if a BMT regime was
able to replace all host microglia with donor cells, what
level of amelioration of stored GlcNS-UA is achievable in
the transplanted MPS IIIA mouse brain? We cultured MPS
IIIA cells (0% normal cells) and determined the relative
level of GlcNS-UA accumulating within them. Additional
cultures were established so that they contained 90% MPS
IIIA cells and 10% normal cells or 80% MPS IIIA cells and
20% normal cells, engraftment levels that may be feasible if
all microglia were donor-derived. We anticipated that
SGSH released from the normal cells would be internalized
by MPS IIIA cells using mannose-6-phosphate receptor-
based mechanisms, subsequently mediating a reduction in
GlcNS-UA in the MPS IIIA cells.
We observed that co-culture of MPS IIIA cells with 10%
normal cells mediated a statistically significant reduction of
14.5% in GlcNS-UA (Fig. 3). This consisted of a 5%
reduction from cross-correction of the MPS IIIA cells by
the input normal cells with the remainder due to a reduced
amount of input GlcNS-UA by the addition of fewer MPS
IIIA cells. Also, co-culture with 20% normal cells enabled a
37% total reduction within the timeframe of the experiment
(21% derived from cross-correction of MPS IIIA cells).
These data are consistent with our in vivo findings (Lau
et al. 2010) and suggest that even if all MPS IIIA brain
microglia/macrophages were able to be replaced with
unaffected donor-derived cells, the level of stored heparan
sulfate–derived substrates may not be reduced beyond
approximately one-third.
Discussion
We evaluated the therapeutic efficacy of BMT in neonatal (3-
day-old) MPS IIIA mice. This equates to approximately
midway through the second trimester of a human fetus in
terms of brain development (Clancy et al. 2001).
A myeloreductive preconditioning regime (4 Gy, 1  106
donor cells delivered intravenously) enabled replacement of
approximately 25% of CD45+ leukocytes of donor origin
and did not result in measurable increases in SGSH activity
in visceral organs or the brain. Subsequently, there was no
effect of treatment on primary or secondary storage
compounds in the brain. Likewise, transplantation of MPS
IIIB mice at 2–4 days of age after irradiation with 2 Gy did
not result in a significant increase in brain NAGLU activity
or ameliorate neuropathology (Heldermon et al. 2010).
These data contrast with those from MPS VII mice, where
transplantation resulted in ~ 4% of wild-type b-glucuroni-
dase activity, focal reductions in lysosomal vacuolization in
the brain and normalization of auditory-evoked brainstem
responses (Sands et al. 1993, 1995). Given that this is a
knockout model, all of the measured b-glucuronidase
would be newly synthesized enzyme. Even greater reduc-
tions in lysosomal storage were observed when higher
irradiation doses were utilized (Sands et al. 1993). Improve-
ments in the accelerating rotor-rod test were also evident in
Twitcher mice, a model of globoid-cell leukodystrophy,




despite brain galactosylceramidase activity not being
significantly increased following treatment (Lin et al.
2007). Twitcher mice transplanted at 8–11 days of age
(9 Gy; 3–5  107 donor cells delivered intraperitoneally)
generated up to 15% normal levels of galactosylceramidase
activity in the brain, which was sufficient to prevent hind-
limb paralysis (Hoogerbrugge et al. 1988). It is evident that
MPS IIIA disease–related factors impair or reduce the
capacity for clinical efficacy to be achieved with BMT in
human MPS III types A, B, and C (Klein et al. 1995;
Shapiro et al. 1995) and murine MPS III types A and B
(Zheng et al. 2004; Heldermon et al. 2010; Lau et al. 2010),
and the growing body of experimental data strongly suggest
that BMT with unmodified cells should not be considered
as a treatment for MPS III.
So why does BMT stabilize neurocognitive function in
some LSD but is unable to resolve the disease pathology in
other disorders? In our study, the SGSH activity generated
under these transplantation conditions was insufficient to
correct primary and secondary storage, which could poten-
tially be explained by a number of reasons. First, inadequate
migration of donor-derived cells into the brain following
transplantation would reduce the number of healthy cells
able to produce SGSH within the brain. It is well-established
that bone marrow-derived cells are capable of migrating
across the blood–brain barrier after myeloablative condition-
ing and then trans-differentiate into microglia, the resident
macrophage population of the brain (e.g., Cogle et al. 2004;
Simard and Rivest 2004). Microglia represent between 5%
and 12% of total brain cells, dependent on the brain region
(Lawson et al. 1990), and considering that proliferation of
resident microglia also contributes up to half of the brain
macrophage pool (Lawson et al. 1992), the absolute maximum
proportion of donor cells that can migrate and repopulate the
brain is less than 12%. Between 0.1–0.2% of recipient brain
cells were found to be of donor origin in the brain of
neonatally-transplanted MPS IIIA mice, and our attempt to
raise the percentage of donor leukocytes in peripheral blood
from 25% (and subsequently increase the proportion of donor
cells within the brain) by increasing the irradiation precondi-
tioning dose to 6 Gy resulted in acute radiation syndrome.
Increased chimerism may be achieved using increased cell
doses or alternate irradiation protocols (e.g., divided dose of
6 Gy). Also, the assessment of additional groups at longer
times post-transplant could possibly have increased the
number of donor-derived cells within the brain.
Quantitative real-time PCR analysis of brain tissue from
adult MPS IIIA mice transplanted in a previous study (where
93% donor-type leukocyte chimerism was achieved) revealed
that donor cells represented only 2.8  1.2% of brain cells
(unpublished data and Lau et al. 2010). BMT did not improve
the behavioral phenotype of these treated MPS IIIA mice.
The low level of donor cell repopulation in the MPS IIIA
mouse brain is unlikely to be the result of a defect in
mobilization of bone marrow–derived cells from the bone
marrow compartment to peripheral blood, as the activity of
two serine proteases involved in cellular mobilization was
similar in normal and MPS IIIA mice. These proteases,
cathepsin G and neutrophil elastase, have been implicated in
altered bone marrow progenitor cell retention/mobilization in
sialidosis mice (Yogalingam et al. 2008). Additionally, no
differences in GFP-expressing donor leukocyte reconstitution
Fig. 3 GlcNS-UA storage in co-cultured normal and MPS IIIA
fibroblasts. Normal-GFP and MPS-GFP cells (5  106 cells in total)
were co-cultured for 48 h at different ratios. The relative amount of
GlcNS-UA was then determined by tandem mass spectrometry and
compared to the untreated group (100% MPS IIIA; filled bars). The
calculated maximum amount of GlcNS-UA in the MPS IIIA cell
portion of each treatment group due to dilution with the normal-GFP
cells is denoted by the open bars (i.e., 90% or 80% of the relative
levels of measured GlcNS-UA measured in the 100% MPS IIIA
cultures). Data are expressed as the mean  SEM. *P < 0.05,
***P < 0.001 versus the untreated group
Fig. 2 (continued) Lysosomal enzyme activity in wild-type cells. (a,
c, e) Murine skin fibroblasts or (b, d, f) mixed neural cell cultures
were harvested at 7 days post-confluence. The amount of (a, b)
intracellular enzyme activity in cell extracts and (c, d) extracellular
enzyme activity in conditioned media samples was determined using
fluorogenic or radiolabeled substrates for SGSH, NAGLU, a-
iduronidase, a-mannosidase, and a-fucosidase. LSD that do not
respond to BMT are depicted by open bars while LSD where BMT
stabilizes neurocognitive decline are depicted by filled bars. (e, f) The
percentage of extracellular activity as a percentage of the total
measured activity for each enzyme is shown. All data are expressed




or the percentage of GFP+ brain cells were measured
between normal and MPS IIIA recipients, suggesting that
movement of donor cells from the vasculature to the brain
was unimpaired in the disease state. This contrasts with the
increased brain repopulation in transplanted metachromatic
leukodystrophy mice (Biffi et al. 2004) and may be one of
the factors contributing to the successful correction of
neurological symptoms in this disorder.
It is possible that even if all microglia were normal in their
enzyme content, this would still be insufficient to generate
enough enzyme activity to mediate clinical improvements.
This concept is supported by data generated in mouse models
of Gaucher disease that either expressed glucosylceramidase
activity in the microglia (and skin) or in skin fibroblasts only
(Enquist et al. 2007). Both models showed neurological
abnormalities, with only marginal delays in the onset of
symptoms and minimal impact on life span. Further, we
demonstrated that even co-culture of MPS IIIA cells with
20% normal cells (a level that cannot be achieved by
transplantation alone) is unable to normalize GlcNS-UA
storage. Co-incubation of approximately equal numbers of
MPS I and MPS II cells (where the MPS I cells provide the
corrective enzyme for the MPS II cells and vice versa) for 48
hours normalizes sulfated glycosaminoglycan storage
(Neufeld and Cantz 1971). Further studies are warranted to
elucidate whether this level of storage reduction can be
achieved in MPS IIIA cells after co-incubation with higher
doses of normal cells and the degree of primary storage
reduction that is required for an impact on clinical
symptoms.
Second, correction of MPS IIIA cells relies on the effective
production and secretion of mannose-6-phosphorylated
SGSH by the donor cells and subsequent cation-independent
mannose-6-phosphate receptor (CI-MPR)-mediated uptake of
SGSH by the neighboring host cells, and thus inadequate
SGSH production, secretion, or endocytosis may also
contribute to the lack of therapeutic benefit in transplanted
MPS IIIA mice. SGSH exhibited the lowest activity in the
intracellular and extracellular fractions of wild-type cells and
this may relate to differences in assay sensitivity (natural
substrate for SGSH versus 4MU-conjugated substrates) or the
natural abundance of the enzymes. However, as each ratio was
measured under identical assay conditions, our calculation of
the ratio of intracellular versus secreted enzyme remains valid.
No relationship was evident between the percentage of
secreted lysosomal enzyme and the efficacy of BMT, with
a-mannosidase and a-fucosidase (enzymes deficient in LSD
that respond to BMT) displaying the highest and lowest
percentage of extracellular enzyme activity, respectively. This
suggests that pathological changes in the relative proportion of
secreted SGSH are not the primary cause for the lack of
correction in MPS IIIA. It remains to be ascertained whether
the CI-MPR is mis-localized in host MPS IIIA cells, thus
reducing the efficiency of exogenous SGSH uptake by
affected cells. Pompe disease fibroblasts showed less efficient
uptake of recombinant a-glucosidase enzyme due to reduced
CI-MPR bioavailability at the plasma membrane, with the
extent of abnormalities closely correlating with disease
severity (Cardone et al. 2008). Increasing the amount of
SGSH produced via ex vivo modification of bone marrow–
derived cells with a gene therapy vector may overcome this
issue (Zheng et al. 2004; Langford-Smith et al. 2012).
In conclusion, BMT was ineffective at ameliorating
primary and secondary storage in the MPS IIIA mouse
brain despite transplantation occurring in the neonatal
period. Further studies are required to elucidate the
mechanism(s) that result in differential responses to
transplantation amongst LSD to direct the design of an
effective BMT-mediated treatment for MPS IIIA.
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Synopsis
Despite intervention in the neonatal period and demonstra-
tion of unimpaired mobilization, engraftment, and secretion
of lysosomal N-sulfoglucosamine sulfohydrolase enzyme
by normal cells, bone marrow transplantation does not
improve neuropathology in the murine MPS IIIA brain.
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